News Extra

Drug company to offer new malaria drug cheaply in Africa

BMJ 2003; 327 doi: https://doi.org/10.1136/bmj.327.7411.360-b (Published 14 August 2003) Cite this as: BMJ 2003;327:360
  1. Stephen Pincock
  1. London

    British pharmaceutical firm GlaxoSmithKline has announced that it will offer its new antimalarial drug at non-profit prices in Africa, after its approval by British regulators.

    The Medicines and Healthcare Products Regulatory Agency has given approval to the combination of chlorproguanil hydrochloride and dapsone, or Lapdap, for uncomplicated Plasmodium falciparum malaria in adults and children weighing over 5 kg.

    The company said it would make the drug available at preferential prices across sub-Saharan Africa as soon as local approval has been granted. The cost to …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe